Myrbetriq (Mirabegron) is a prescription medication for adults used to treat certain bladder problems (overactive bladder, neurogenic detrusor overactivity). Mirabegron is a beta-3-adrenergic receptor agonist, an alternative OAB treatment to antimuscarinics. It works by relaxing the bladder muscle (detrusor), which helps the bladder hold more urine and reduces symptoms of an overactive bladder. Other alternative drugs include Vesicare, Ditropan, Toviaz.
In a study (A Prospective, Randomized, Placebo-Controlled Pilot Study of Mirabegron (Myrbetriq) and Behavioral Modification for Overactive Bladder in Parkinson Disease (908), April 14, 2020), P Agarwal, T Brown, S Ray, A Madan, I Roy-Faderman, found that “Mirabegron was safe and well-tolerated in this PD (Parkinson disease) population.”
In another clinical trial (STOMp: sexual function trial of overactive bladder medication, January 12, 2023), Allison Polland, MD, found that “Female sexual function has been shown to improve with overactive bladder (OAB) treatment”.
Manufacturer Information
The brand Myrbetriq, manufactured by Astellas Pharma, is available in Canada, Turkey, and the United Kingdom. It is available in strengths of 25 mg and 50 mg. Generic Mirabegron is manufactured in India by Sun Pharma and is also known as Mirago. We also supply in different quantities; please call our toll-free number at 1.877.745.9217 for more details.
• Betanis (Commonly used in Japan and other Asian markets)
• Betmiga (The primary brand name used in Europe, Canada, and the United Kingdom)
• Mirabegron (The global generic name for the active ingredient)
• Myrbetriq (The primary brand name used in the United States and Canada)
• Myrbetriq Granules (A specific formulation for pediatric patients or those who have difficulty swallowing tablets)